Skip to content

RIFADINE 300 mg

DRUG4 trials

Sponsors

Institut Pasteur, Centre Hospitalier Universitaire De Nantes, Centre Hospitalier Universitaire Amiens Picardie, Centre Hospitalier De Tourcoing

Conditions

Adult with an staphylococcal prosthetic joint infection treated with debridementHurley stage 2 active Hidradenitis SuppurativaIs to demonstrate a non inferior efficacy of azithromycin and so the possibility for clinician to choose between two drugs for Mycobacterium avium complex treatment.antibiotics and implant retention (DAIR strategy)staphylococcal endocarditis

Phase 3

A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients versus Tetracycline Derivative (ABCESS2)
RecruitingCTIS2023-505818-16-00
Institut PasteurHurley stage 2 active Hidradenitis Suppurativa
Start: 2025-05-22Target: 92Updated: 2026-01-15
CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective controlled study (CLAZI)
RecruitingCTIS2024-518578-15-00
Centre Hospitalier Universitaire Amiens PicardieIs to demonstrate a non inferior efficacy of azithromycin and so the possibility for clinician to choose between two drugs for Mycobacterium avium complex treatment.
Start: 2018-02-05Target: 424Updated: 2026-01-23
RIFAMAB : Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-label, non-inferiority trial
Not yet recruitingCTIS2024-519894-20-01
Centre Hospitalier De TourcoingAdult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
Target: 436Updated: 2025-02-07
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
Not yet recruitingCTIS2024-518018-22-00
Centre Hospitalier Universitaire De Nantesstaphylococcal endocarditis
Target: 422Updated: 2025-08-28